Ultrasound Report Summary - Mrs. Samima Halder, 46F

1. Left VUJ (Vesicoureteric Junction) Calculus with Hydroureteronephrosis

Assessment

• Largest stone: 0.48 cm (4.8 mm) at left VUJ
• At least 3 calculi in the left ureter
• Mild left ureteral dilatation + left hydronephrosis (left kidney 10.3 cm vs right 9.4 cm)
• Right kidney and ureter - normal

Conservative Management (first-line for stones <10 mm)

• Medical Expulsive Therapy (MET): Tamsulosin 0.4 mg once daily - an alpha-blocker that relaxes ureteral smooth muscle and aids spontaneous stone passage (especially effective for distal/VUJ stones)
• Hydration: High fluid intake (>2.5 L/day) to promote passage
• Analgesia: NSAIDs (diclofenac 75 mg) or paracetamol for pain; avoid NSAIDs if renal function is compromised
• Urine straining: To capture stone for composition analysis

Monitoring

• Urinalysis + urine culture (rule out concurrent UTI/pyelonephritis - very important with obstruction)
• Serum creatinine, BUN, electrolytes - to assess renal function
• Repeat ultrasound in 2-4 weeks

Urgent/Surgical Indications - Refer immediately if any of:

• Fever/signs of infection (risk of urosepsis - life-threatening emergency)
• Severe uncontrolled pain
• Worsening renal function
• Stone fails to pass after 4-6 weeks

Surgical Options (if conservative fails)

• Ureteroscopy (URS) with laser lithotripsy - first-line for distal ureteral/VUJ stones; highly effective
• ESWL (Extracorporeal Shock Wave Lithotripsy) - alternative if URS not available
• Ureteral stenting/nephrostomy - if obstruction causes renal deterioration or infection

Stone Prevention (long-term)

• Increase fluid intake to >2 L/day (most important single intervention)
• Reduce sodium and animal protein intake
• Stone composition analysis to guide specific dietary changes
• If calcium oxalate stones: reduce oxalate-rich foods (spinach, nuts, chocolate)

2. Hepatomegaly with Grade I Fatty Changes (Non-Alcoholic Fatty Liver Disease - NAFLD)

Investigations Recommended

• Liver function tests (ALT, AST, ALP, bilirubin, albumin)
• Fasting blood glucose + HbA1c (rule out diabetes)
• Fasting lipid profile (dyslipidemia is the most common association)
• BMI and waist circumference assessment
• Thyroid function test (hypothyroidism causes fatty liver)
• Hepatitis B and C serology

Management

• Weight loss: 5-10% body weight reduction significantly reduces hepatic fat; target >7-10% for histological improvement
• Diet: Low-calorie, low-fat, low-refined-carbohydrate diet; Mediterranean diet is well-supported
• Exercise: Aerobic exercise 150-200 min/week (e.g., brisk walking, swimming); even without weight loss, exercise reduces liver fat
• Alcohol: Avoid completely
• Avoid hepatotoxic drugs: Paracetamol in moderation only; avoid herbal remedies without medical advice

• Treat underlying dyslipidemia (statins are safe in NAFLD)
• Treat insulin resistance (metformin if diabetic; pioglitazone has evidence for NASH)
• Vitamin E (800 IU/day) - has evidence in non-diabetic NASH (discuss with physician)
• No specific FDA-approved drug exists for Grade I NAFLD alone - lifestyle remains primary

• Repeat LFTs in 3 months
• Repeat ultrasound in 6 months to assess response
• If no improvement or LFTs worsen - refer to gastroenterologist/hepatologist

3. Bulky Uterus

Likely Causes

• Adenomyosis (most common cause of bulky uterus in a 46-year-old - endometrial glands embedded in myometrium)
• Uterine fibroids (though no discrete mass reported - diffuse enlargement possible)
• Normal variant in a parous woman (needs correlation with parity)

Investigations Recommended

• Detailed menstrual history: dysmenorrhea, menorrhagia, dyspareunia? (key features of adenomyosis)
• MRI pelvis - gold standard for confirming adenomyosis vs fibroids
• CA-125 level (though non-specific, can support adenomyosis)
• Hemoglobin (if heavy periods - assess for anemia)

Management (depends on symptoms)

• Reassurance and watchful waiting
• Annual follow-up ultrasound

• Hormonal therapy (first-line):
  • Levonorgestrel-releasing IUD (Mirena) - most effective for heavy menstrual bleeding from adenomyosis, reduces uterine size
  • Combined oral contraceptive pills (OCP)
  • Progestins (norethisterone, dienogest)
  • GnRH analogues (temporary use, induces pseudo-menopause) - use before surgery or as bridge
• NSAIDs: Mefenamic acid for dysmenorrhea
• Tranexamic acid: For heavy menstrual bleeding

• Hysterectomy - definitive treatment for adenomyosis (at 46 years old, may be appropriate if family complete)
• Endometrial ablation - for bleeding-dominant cases

Summary Action Plan

Important disclaimer: This analysis is for educational/informational purposes. The treating clinician must correlate these findings with the patient's full clinical history, symptoms, examination findings, and lab work before initiating any treatment. Please ensure the patient is seen by a urologist, physician, and gynecologist as appropriate.